Tyra Biosciences, Inc.

CARLSBAD, CA · CIK 0001863127 · Biotech · Public

Oral small-molecule kinase inhibitor (dabogratinib) for skeletal dysplasia and urologic cancers

tyra.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$200M
1 Form D · Feb 2024
32 months since last filing
Contracts
—
No federal contracts on record
Patents
40
3 granted · 37 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$199,999,934
Form D · SECPress

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1266MOLECULAR TECHNOLOGIES LABORATORIES LLC——
1267MARTINGALE LABS, INC.——
1268Monte Rosa Therapeutics, Inc.—$143M
1269Tyra Biosciences, Inc.—$200M
1270NEUROEPIGENIX, LLC——
1271Third Harmonic Bio——
1272BridgeBio Oncology Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

1 article · matched on company name

Founders & Team

From Form D filings · 12 related persons
  • Daniel BensenExecutive Officer
  • Isan Chen, M.D.Director
  • Alan FuhrmanExecutive Officer
  • Todd Harris, Ph.D.Director · Executive Officer
  • Gilla Kaplan, Ph.D.Director
  • Nina KjellsonDirector
  • Melissa McCracken, Ph.D.Director
  • Robert MoreDirector
  • Jake Simson, Ph.D.Director
  • Sid Subramony, Ph.D.Director
  • Hiroomi Tada, M.D., Ph.D.Executive Officer
  • Rehan VerjeeDirector

Patents

USPTO · 3 granted of 40
  • FGFR3 Inhibitor Compoundsapplication
  • Methods Of Treating Solid Tumors Having Activation FGFR3 Gene Alterationsapplication
  • Indazole Compoundsapplication
  • Therapies With Ppar Agonists And FGFR4 Inhibitorsapplication
  • Indazole Compounds As Kinase Inhibitorsapplication
  • Indazole Compoundsgranted
  • Indazole Compounds As Kinase Inhibitorsgranted
  • Indazole Compoundsapplication
  • Indazole Compounds As Kinase Inhibitorsgranted
  • Aminopyrimidine Compounds And Methods Of Their Useapplication
  • Aminopyrimidine Compoundsapplication
  • Methods of Treating Children with Achondroplasiaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.